The role of Tc-99m MIBI scintigraphy in clinical T1 renal mass assessment: Does it have a real benefit?

Asi T., Tuncali M., Tuncel M., Alkanat N., Hazir B., Kösemehmetoğlu K., ...More

Urologic oncology, vol.38, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 38
  • Publication Date: 2020
  • Doi Number: 10.1016/j.urolonc.2020.07.018
  • Journal Name: Urologic oncology
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CINAHL, EMBASE, MEDLINE
  • Keywords: Tc-99m MIBI scintigraphy, Renal mass, Benign vs. malignant, Oncocytoma vs. RCC, MDR pump, CELL CARCINOMA, ONCOCYTOMA, TC-99M-SESTAMIBI, DIFFERENTIATION, DIAGNOSIS, ACCURACY, SPECT/CT, FEATURES, TUMORS
  • Hacettepe University Affiliated: Yes


Introduction: Despite the increasing accuracy of imaging modalities, the rate of benign renal tumors misclassified as malignant before surgery still non-negligible. Tc-99m sestamibi was demonstrated to be a possible reliable agent in discriminating oncocytoma from renal cell carcinoma (RCC). We aimed to study the efficacy of Tc-99m MIBI tumor scintigraphy in evaluating clinical T1 renal masses.